{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:53:23Z","timestamp":1794243203145,"version":"4.9.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41584-026-01420-3","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:32:09Z","timestamp":1787239929000},"page":"643-662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis"],"prefix":"10.1038","volume":"22","author":[{"given":"Alexandra","family":"Audemard-Verger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evang\u00e9line","family":"Pillebout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Baier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg M.","family":"Bajema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-1406","authenticated-orcid":false,"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-9941","authenticated-orcid":false,"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-853X","authenticated-orcid":false,"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0938","authenticated-orcid":false,"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2598-5806","authenticated-orcid":false,"given":"Haner","family":"Direskeneli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Errichiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-7406","authenticated-orcid":false,"given":"Miguel A.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-3720","authenticated-orcid":false,"given":"Ahmet","family":"G\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hankard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alojzija","family":"Ho\u010devar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jachiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Jelusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Jourde-Chiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred D.","family":"Mahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Oni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2883-7868","authenticated-orcid":false,"given":"Seza","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-9092","authenticated-orcid":false,"given":"Alan D.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cord","family":"Sunderk\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-4402","authenticated-orcid":false,"given":"Giorgio","family":"Trivioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":false,"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-9172","authenticated-orcid":false,"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the collaborators of the EUGAVAS Study Group on behalf of the European Vasculitis Society (EUVAS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Brolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Bygum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Maisons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"1420_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/annrheumdis-2018-214142","volume":"78","author":"A Tracy","year":"2019","unstructured":"Tracy, A. et al. Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Sch\u00f6nlein purpura): a retrospective cohort study using routinely collected primary care data. Ann. Rheum. Dis. 78, 261\u2013269 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1420_CR2","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/art.40178","volume":"69","author":"A Audemard-Verger","year":"2017","unstructured":"Audemard-Verger, A. et al. Characteristics and management of IgA vasculitis (Henoch-Sch\u00f6nlein) in adults: data from 260 patients included in a French multicenter retrospective survey. Arthritis Rheumatol. 69, 1862\u20131870 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1420_CR3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(02)11279-7","volume":"360","author":"JM Gardner-Medwin","year":"2002","unstructured":"Gardner-Medwin, J. M., Dolezalova, P., Cummins, C. & Southwood, T. R. Incidence of Henoch-Sch\u00f6nlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360, 1197\u20131202 (2002).","journal-title":"Lancet"},{"key":"1420_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/rheumatology\/keh544","volume":"44","author":"YH Yang","year":"2005","unstructured":"Yang, Y. H. et al. A nationwide survey on epidemiological characteristics of childhood Henoch-Sch\u00f6nlein purpura in Taiwan. Rheumatology 44, 618\u2013622 (2005).","journal-title":"Rheumatology"},{"key":"1420_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.berh.2004.11.006","volume":"19","author":"RA Watts","year":"2005","unstructured":"Watts, R. A., Lane, S. & Scott, D. G. What is known about the epidemiology of the vasculitides? Best Pract. Res. Clin. Rheumatol. 19, 191\u2013207 (2005).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"1420_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/00005792-199909000-00002","volume":"78","author":"MA Gonzalez-Gay","year":"1999","unstructured":"Gonzalez-Gay, M. A. & Garcia-Porrua, C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine 78, 292\u2013308 (1999).","journal-title":"Medicine"},{"key":"1420_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70083","volume":"7","author":"A Gage","year":"2025","unstructured":"Gage, A., Pepper, R. J., Marro, J., Salama, A. D. & Oni, L. IgA vasculitis across the ages: is it time for a precision medicine approach? ACR Open Rheumatol. 7, e70083 (2025).","journal-title":"ACR Open Rheumatol."},{"key":"1420_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003822","author":"M Thalen","year":"2024","unstructured":"Thalen, M. et al. Epidemiology and clinical characteristics of biopsy-confirmed adult-onset IgA vasculitis in southern Sweden. RMD Open https:\/\/doi.org\/10.1136\/rmdopen-2023-003822 (2024).","journal-title":"RMD Open"},{"key":"1420_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jiph.2019.07.004","volume":"13","author":"JJ Wang","year":"2020","unstructured":"Wang, J. J. et al. Association of the infectious triggers with childhood Henoch-Sch\u00f6nlein purpura in Anhui province, China. J. Infect. Public Health 13, 110\u2013117 (2020).","journal-title":"J. Infect. Public Health"},{"key":"1420_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012217","volume":"97","author":"HH Hwang","year":"2018","unstructured":"Hwang, H. H., Lim, I. S., Choi, B. S. & Yi, D. Y. Analysis of seasonal tendencies in pediatric Henoch-Sch\u00f6nlein purpura and comparison with outbreak of infectious diseases. Medicine 97, e12217 (2018).","journal-title":"Medicine"},{"key":"1420_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/03009742.2017.1412497","volume":"47","author":"M Mossberg","year":"2018","unstructured":"Mossberg, M., Segelmark, M., Kahn, R., Englund, M. & Mohammad, A. J. Epidemiology of primary systemic vasculitis in children: a population-based study from southern Sweden. Scand. J. Rheumatol. 47, 295\u2013302 (2018).","journal-title":"Scand. J. Rheumatol."},{"key":"1420_CR12","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s00296-023-05387-2","volume":"43","author":"V Maisons","year":"2023","unstructured":"Maisons, V. et al. New insights into epidemiological data and impact of the COVID-19 pandemic on IgA vasculitis in children and adults: a French nationwide cohort. Rheumatol. Int. 43, 1791\u20131798 (2023).","journal-title":"Rheumatol. Int."},{"key":"1420_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3899\/jrheum.190110","volume":"47","author":"JC Nossent","year":"2020","unstructured":"Nossent, J. C., Raymond, W., Keen, H., Preen, D. B. & Inderjeeth, C. A. Infection rates before and after diagnosis of iga vasculitis in childhood: a population-wide study using non-exposed matched controls. J. Rheumatol. 47, 424\u2013430 (2020).","journal-title":"J. Rheumatol."},{"key":"1420_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/00005792-199911000-00005","volume":"78","author":"FT Saulsbury","year":"1999","unstructured":"Saulsbury, F. T. Henoch-Sch\u00f6nlein purpura in children. Report of 100 patients and review of the literature. Medicine 78, 395\u2013409 (1999).","journal-title":"Medicine"},{"key":"1420_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/MD.0000000000000019","volume":"93","author":"V Calvo-Rio","year":"2014","unstructured":"Calvo-Rio, V. et al. Henoch-Sch\u00f6nlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine 93, 106\u2013113 (2014).","journal-title":"Medicine"},{"key":"1420_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1210307","volume":"10","author":"A Ho\u010devar","year":"2023","unstructured":"Ho\u010devar, A., Ostrovrsnik, J., Jurcic, V., Tomsic, M. & Rotar, Z. Short-term outcome of patients with adult IgA vasculitis: a single-center experience. Front. Med. 10, 1210307 (2023).","journal-title":"Front. Med."},{"key":"1420_CR17","first-page":"S77","volume":"34","author":"S Hong","year":"2016","unstructured":"Hong, S. et al. Late-onset IgA vasculitis in adult patients exhibits distinct clinical characteristics and outcomes. Clin. Exp. Rheumatol. 34, S77\u2013S83 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1420_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/rheumatology\/keae030","volume":"64","author":"J Stanway","year":"2025","unstructured":"Stanway, J. et al. IgA vasculitis nephritis-outcomes in adult-onset disease. Rheumatology 64, 690\u2013696 (2025).","journal-title":"Rheumatology"},{"key":"1420_CR19","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1093\/rheumatology\/keaa921","volume":"60","author":"A Audemard-Verger","year":"2021","unstructured":"Audemard-Verger, A. et al. Impact of aging on phenotype and prognosis in IgA vasculitis. Rheumatology 60, 4245\u20134251 (2021).","journal-title":"Rheumatology"},{"key":"1420_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01013-x","volume":"23","author":"K Yaseen","year":"2021","unstructured":"Yaseen, K., Herlitz, L. C. & Villa-Forte, A. IgA vasculitis in adults: a rare yet challenging disease. Curr. Rheumatol. Rep. 23, 50 (2021).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1420_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2014.126","volume":"10","author":"JC Davin","year":"2014","unstructured":"Davin, J. C. & Coppo, R. Henoch-Sch\u00f6nlein purpura nephritis in children. Nat. Rev. Nephrol. 10, 563\u2013573 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"1420_CR22","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s00467-007-0623-y","volume":"22","author":"KK Lau","year":"2007","unstructured":"Lau, K. K. et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Sch\u00f6nlein purpura. Pediatr. Nephrol. 22, 2067\u20132072 (2007).","journal-title":"Pediatr. Nephrol."},{"key":"1420_CR23","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.ekir.2019.08.015","volume":"4","author":"H Suzuki","year":"2019","unstructured":"Suzuki, H., Moldoveanu, Z., Julian, B. A., Wyatt, R. J. & Novak, J. Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis. Kidney Int. Rep. 4, 1717\u20131724 (2019).","journal-title":"Kidney Int. Rep."},{"key":"1420_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","volume":"93","author":"H Suzuki","year":"2018","unstructured":"Suzuki, H. et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 93, 700\u2013705 (2018).","journal-title":"Kidney Int."},{"key":"1420_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1681\/ASN.0000000534","volume":"36","author":"R Lafayette","year":"2025","unstructured":"Lafayette, R. et al. Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial. J. Am. Soc. Nephrol. 36, 645\u2013656 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1420_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic, V. et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N. Engl. J. Med. 392, 531\u2013543 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1420_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/ndt\/gfae143","volume":"40","author":"J Friedrich","year":"2024","unstructured":"Friedrich, J., Bellmann, M., Klank, D., Porubsky, S. & Bergner, R. Clinical and histological comparison of IgA nephritis and renal IgA vasculitis. Nephrol. Dial. Transpl. 40, 182\u2013192 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1420_CR28","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.kint.2025.07.038","volume":"108","author":"L Novak","year":"2025","unstructured":"Novak, L. et al. Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis. Kidney Int. 108, 1158\u20131169 (2025).","journal-title":"Kidney Int."},{"key":"1420_CR29","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/ndt\/13.4.930","volume":"13","author":"AC Allen","year":"1998","unstructured":"Allen, A. C., Willis, F. R., Beattie, T. J. & Feehally, J. Abnormal IgA glycosylation in Henoch-Sch\u00f6nlein purpura restricted to patients with clinical nephritis. Nephrol. Dial. Transpl. 13, 930\u2013934 (1998).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1420_CR30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00467-021-04950-y","volume":"37","author":"MC Hastings","year":"2022","unstructured":"Hastings, M. C. et al. IgA vasculitis with nephritis: update of pathogenesis with clinical implications. Pediatr. Nephrol. 37, 719\u2013733 (2022).","journal-title":"Pediatr. Nephrol."},{"key":"1420_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/archderm.1997.03890400034005","volume":"133","author":"E Tancrede-Bohin","year":"1997","unstructured":"Tancrede-Bohin, E. et al. Sch\u00f6nlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. Arch. Dermatol. 133, 438\u2013442 (1997).","journal-title":"Arch. Dermatol."},{"key":"1420_CR32","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","volume":"16","author":"MH Heineke","year":"2017","unstructured":"Heineke, M. H. et al. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Sch\u00f6nlein purpura). Autoimmun. Rev. 16, 1246\u20131253 (2017).","journal-title":"Autoimmun. Rev."},{"key":"1420_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2026.106742","volume":"147","author":"V Maisons","year":"2026","unstructured":"Maisons, V. et al. Identifying distinct clinical phenotypes and outcomes in adult-onset IgA vasculitis using unsupervised clustering analysis. Eur. J. Intern. Med. 147, 106742 (2026).","journal-title":"Eur. J. Intern. Med."},{"key":"1420_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23638-2","volume":"8","author":"X Huang","year":"2018","unstructured":"Huang, X. et al. Renal prognosis and related risk factors for Henoch-Sch\u00f6nlein purpura nephritis: a Chinese adult patient cohort. Sci. Rep. 8, 5585 (2018).","journal-title":"Sci. Rep."},{"key":"1420_CR35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/01.ASN.0000013883.99976.22","volume":"13","author":"E Pillebout","year":"2002","unstructured":"Pillebout, E. et al. Henoch-Sch\u00f6nlein purpura in adults: outcome and prognostic factors. J. Am. Soc. Nephrol. 13, 1271\u20131278 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1420_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.zefq.2017.10.008","volume":"127-128","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. A reporting tool for practice guidelines in health care: the RIGHT statement [German]. Z. Evid. Fortbild. Qual. Gesundhwes 127-128, 3\u201310 (2017).","journal-title":"Z. Evid. Fortbild. Qual. Gesundhwes"},{"key":"1420_CR37","unstructured":"Oxford Centre for Evidence-Based Medicine. Levels of evidence (March 2009). Centre for Evidence-Based Medicine https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 (2009)."},{"key":"1420_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette, J. C. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65, 1\u201311 (2013).","journal-title":"Arthritis Rheum."},{"key":"1420_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/art.40375","volume":"70","author":"CH Sunderkotter","year":"2018","unstructured":"Sunderkotter, C. H. et al. Nomenclature of cutaneous vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol. 70, 171\u2013184 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1420_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archderm.134.3.309","volume":"134","author":"G Sais","year":"1998","unstructured":"Sais, G. et al. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch. Dermatol. 134, 309\u2013315 (1998).","journal-title":"Arch. Dermatol."},{"key":"1420_CR41","first-page":"479","volume":"23","author":"L Herda","year":"2025","unstructured":"Herda, L., Michl, C. & Sunderkotter, C. High detection rate for perivascular deposits of immunoglobulins in immune complex vasculitis from biopsies of early macular lesions. J. Dtsch. Dermatol. Ges. 23, 479\u2013485 (2025).","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"1420_CR42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/DAD.0000000000000122","volume":"36","author":"M Alalwani","year":"2014","unstructured":"Alalwani, M., Billings, S. D. & Gota, C. E. Clinical significance of immunoglobulin deposition in leukocytoclastic vasculitis: a 5-year retrospective study of 88 patients at cleveland clinic. Am. J. Dermatopathol. 36, 723\u2013729 (2014).","journal-title":"Am. J. Dermatopathol."},{"key":"1420_CR43","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/DAD.0000000000001170","volume":"40","author":"K Lath","year":"2018","unstructured":"Lath, K. et al. Role of direct immunofluorescence in cutaneous small-vessel vasculitis: experience from a tertiary center. Am. J. Dermatopathol. 40, 661\u2013666 (2018).","journal-title":"Am. J. Dermatopathol."},{"key":"1420_CR44","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/art.1780330809","volume":"33","author":"JA Mills","year":"1990","unstructured":"Mills, J. A. et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Sch\u00f6nlein purpura. Arthritis Rheum. 33, 1114\u20131121 (1990).","journal-title":"Arthritis Rheum."},{"key":"1420_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"JC Jennette","year":"1994","unstructured":"Jennette, J. C. et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37, 187\u2013192 (1994).","journal-title":"Arthritis Rheum."},{"key":"1420_CR46","first-page":"1668","volume":"119","author":"H Suzuki","year":"2009","unstructured":"Suzuki, H. et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest. 119, 1668\u20131677 (2009).","journal-title":"J. Clin. Invest."},{"key":"1420_CR47","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/ard.2009.116657","volume":"69","author":"S Ozen","year":"2010","unstructured":"Ozen, S. et al. EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann. Rheum. Dis. 69, 798\u2013806 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1420_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0959-4","volume":"18","author":"A Ho\u010devar","year":"2016","unstructured":"Ho\u010devar, A. et al. IgA vasculitis in adults: the performance of the EULAR\/PRINTO\/PRES classification criteria in adults. Arthritis Res. Ther. 18, 58 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"1420_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005728","author":"Y Bayindir","year":"2025","unstructured":"Bayindir, Y. et al. Performance in adults of the EULAR\/PRINTO\/PRES (Ankara 2008) classification criteria for IgA vasculitis. RMD Open https:\/\/doi.org\/10.1136\/rmdopen-2025-005728 (2025).","journal-title":"RMD Open"},{"key":"1420_CR50","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.autrev.2015.02.003","volume":"14","author":"A Audemard-Verger","year":"2015","unstructured":"Audemard-Verger, A., Pillebout, E., Guillevin, L., Thervet, E. & Terrier, B. IgA vasculitis (Henoch-Sh\u00f6nlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun. Rev. 14, 579\u2013585 (2015).","journal-title":"Autoimmun. Rev."},{"key":"1420_CR51","first-page":"53","volume":"72","author":"CN Inoue","year":"2011","unstructured":"Inoue, C. N. et al. Periodontal and ENT therapy in the treatment of pediatric Henoch-Sch\u00f6nlein purpura and IgA nephropathy. Adv. Otorhinolaryngol. 72, 53\u201356 (2011).","journal-title":"Adv. Otorhinolaryngol."},{"key":"1420_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102707","volume":"20","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen, C. et al. Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance-based approach. Autoimmun. Rev. 20, 102707 (2021).","journal-title":"Autoimmun. Rev."},{"key":"1420_CR53","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3899\/jrheum.220545","volume":"50","author":"Y Ramdani","year":"2023","unstructured":"Ramdani, Y. et al. IgA vasculitis following COVID-19 vaccination: a French multicenter case series including 12 patients. J. Rheumatol. 50, 252\u2013257 (2023).","journal-title":"J. Rheumatol."},{"key":"1420_CR54","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1111\/jdv.19411","volume":"38","author":"M Toker","year":"2024","unstructured":"Toker, M. et al. IgA vasculitis and malignancy: a systematic review. J. Eur. Acad. Dermatol. Venereol. 38, e41\u2013e44 (2024).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1420_CR55","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s10067-020-05455-z","volume":"40","author":"A Hankard","year":"2021","unstructured":"Hankard, A. et al. New insights on IgA vasculitis with underlying solid tumor: a nationwide French study of 30 patients. Clin. Rheumatol. 40, 1933\u20131940 (2021).","journal-title":"Clin. Rheumatol."},{"key":"1420_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1551772","volume":"12","author":"A Ho\u010devar","year":"2025","unstructured":"Ho\u010devar, A., Jurcic, V. & Rotar, Z. The association between adult IgA vasculitis and cancer: a prospective observational study. Front. Med. 12, 1551772 (2025).","journal-title":"Front. Med."},{"key":"1420_CR57","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3899\/jrheum.200293","volume":"48","author":"I Elhani","year":"2021","unstructured":"Elhani, I. et al. IgA vasculitis with underlying liver cirrhosis: a French nationwide case series of 20 patients. J. Rheumatol. 48, 735\u2013740 (2021).","journal-title":"J. Rheumatol."},{"key":"1420_CR58","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.mayocp.2019.04.034","volume":"94","author":"M Villatoro-Villar","year":"2019","unstructured":"Villatoro-Villar, M. et al. Clinical characteristics of biopsy-proven IgA vasculitis in children and adults: a retrospective cohort study. Mayo Clin. Proc. 94, 1769\u20131780 (2019).","journal-title":"Mayo Clin. Proc."},{"key":"1420_CR59","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1093\/rheumatology\/keaa104","volume":"59","author":"A Audemard-Verger","year":"2020","unstructured":"Audemard-Verger, A. et al. Gastrointestinal involvement in adult IgA vasculitis (Henoch-Sch\u00f6nlein purpura): updated picture from a French multicentre and retrospective series of 260 cases. Rheumatology 59, 3050\u20133057 (2020).","journal-title":"Rheumatology"},{"key":"1420_CR60","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S0016-5107(02)70376-3","volume":"56","author":"M Esaki","year":"2002","unstructured":"Esaki, M. et al. GI involvement in Henoch-Sch\u00f6nlein purpura. Gastrointest. Endosc. 56, 920\u2013923 (2002).","journal-title":"Gastrointest. Endosc."},{"key":"1420_CR61","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015643","volume":"98","author":"Y Han","year":"2019","unstructured":"Han, Y. et al. Endoscopic and microscopic findings of gastrointestinal tract in Henoch-Sch\u00f6nlein purpura: single institute experience with review of literature. Medicine 98, e15643 (2019).","journal-title":"Medicine"},{"key":"1420_CR62","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/PAS.0000000000001036","volume":"42","author":"CY Louie","year":"2018","unstructured":"Louie, C. Y., Gomez, A. J., Sibley, R. K., Bass, D. & Longacre, T. A. Histologic features of gastrointestinal tract biopsies in IgA vasculitis (Henoch-Sch\u00f6nlein purpura). Am. J. Surg. Pathol. 42, 529\u2013533 (2018).","journal-title":"Am. J. Surg. Pathol."},{"key":"1420_CR63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/sarh.2002.33980","volume":"32","author":"C Garcia-Porrua","year":"2002","unstructured":"Garcia-Porrua, C., Calvino, M. C., Llorca, J., Couselo, J. M. & Gonzalez-Gay, M. A. Henoch-Sch\u00f6nlein purpura in children and adults: clinical differences in a defined population. Semin. Arthritis Rheum. 32, 149\u2013156 (2002).","journal-title":"Semin. Arthritis Rheum."},{"key":"1420_CR64","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3346\/jkms.2014.29.2.198","volume":"29","author":"Y Kang","year":"2014","unstructured":"Kang, Y. et al. Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Sch\u00f6nlein purpura. J. Korean Med. Sci. 29, 198\u2013203 (2014).","journal-title":"J. Korean Med. Sci."},{"key":"1420_CR65","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1875-9572(09)60056-5","volume":"50","author":"SP Hung","year":"2009","unstructured":"Hung, S. P. et al. Clinical manifestations and outcomes of Henoch-Sch\u00f6nlein purpura: comparison between adults and children. Pediatr. Neonatol. 50, 162\u2013168 (2009).","journal-title":"Pediatr. Neonatol."},{"key":"1420_CR66","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/qjmed\/hcl034","volume":"99","author":"S Shrestha","year":"2006","unstructured":"Shrestha, S. et al. Henoch Sch\u00f6nlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. QJM 99, 253\u2013265 (2006).","journal-title":"QJM"},{"key":"1420_CR67","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2215\/CJN.0000000000000398","volume":"19","author":"SJ Barbour","year":"2024","unstructured":"Barbour, S. J. et al. Histologic and clinical factors associated with kidney outcomes in IgA vasculitis nephritis. Clin. J. Am. Soc. Nephrol. 19, 438\u2013451 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1420_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf324","volume":"18","author":"E Stamellou","year":"2025","unstructured":"Stamellou, E. et al. The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective. Clin. Kidney J. 18, sfaf324 (2025).","journal-title":"Clin. Kidney J."},{"key":"1420_CR69","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfag003","volume":"19","author":"J Floege","year":"2026","unstructured":"Floege, J., Fervenza, F. C. & Coppo, R. Microscopic hematuria in IgA nephropathy: a biomarker of disease activity. Clin. Kidney J. 19, sfag003 (2026).","journal-title":"Clin. Kidney J."},{"key":"1420_CR70","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1159\/000501459","volume":"44","author":"J Tan","year":"2019","unstructured":"Tan, J. et al. The clinicopathological characteristics of Henoch-Sch\u00f6nlein purpura nephritis with presentation of nephrotic syndrome. Kidney Blood Press. Res. 44, 754\u2013764 (2019).","journal-title":"Kidney Blood Press. Res."},{"key":"1420_CR71","doi-asserted-by":"publisher","first-page":"c16","DOI":"10.1159\/000210570","volume":"112","author":"T Pankhurst","year":"2009","unstructured":"Pankhurst, T. et al. Vasculitic IgA nephropathy: prognosis and outcome. Nephron Clin. Pract. 112, c16\u2013c24 (2009).","journal-title":"Nephron Clin. Pract."},{"key":"1420_CR72","first-page":"S45","volume":"31","author":"V Calvo-Rio","year":"2013","unstructured":"Calvo-Rio, V. et al. Henoch-Sch\u00f6nlein purpura nephritis and IgA nephropathy: a comparative clinical study. Clin. Exp. Rheumatol. 31, S45\u2013S51 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1420_CR73","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ki.2012.302","volume":"82","author":"HJ Oh","year":"2012","unstructured":"Oh, H. J. et al. Clinical outcomes, when matched at presentation, do not vary between adult-onset Henoch-Sch\u00f6nlein purpura nephritis and IgA nephropathy. Kidney Int. 82, 1304\u20131312 (2012).","journal-title":"Kidney Int."},{"key":"1420_CR74","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/ndt\/12.11.2277","volume":"12","author":"R Coppo","year":"1997","unstructured":"Coppo, R., Mazzucco, G., Cagnoli, L., Lupo, A. & Schena, F. P. Long-term prognosis of Henoch-Sch\u00f6nlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Sch\u00f6nlein purpura. Nephrol. Dial. Transpl. 12, 2277\u20132283 (1997).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1420_CR75","doi-asserted-by":"publisher","first-page":"ii19","DOI":"10.1093\/ckj\/sfad232","volume":"16","author":"L Zand","year":"2023","unstructured":"Zand, L., Fervenza, F. C. & Coppo, R. Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients. Clin. Kidney J. 16, ii19\u2013ii27 (2023).","journal-title":"Clin. Kidney J."},{"key":"1420_CR76","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1681\/ASN.2017010108","volume":"28","author":"AM Sevillano","year":"2017","unstructured":"Sevillano, A. M. et al. Remission of hematuria improves renal survival in IgA nephropathy. J. Am. Soc. Nephrol. 28, 3089\u20133099 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1420_CR77","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2215\/CJN.04710420","volume":"15","author":"ED Poggio","year":"2020","unstructured":"Poggio, E. D. et al. Systematic review and meta-analysis of native kidney biopsy complications. Clin. J. Am. Soc. Nephrol. 15, 1595\u20131602 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1420_CR78","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00467-017-3608-5","volume":"32","author":"M Koskela","year":"2017","unstructured":"Koskela, M. et al. The ISKDC classification and a new semiquantitative classification for predicting outcomes of Henoch-Sch\u00f6nlein purpura nephritis. Pediatr. Nephrol. 32, 1201\u20131209 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"1420_CR79","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10238-019-00567-6","volume":"19","author":"ZX Zhong","year":"2019","unstructured":"Zhong, Z. X. et al. Crescent lesions are not a predictive factor in adult-onset Henoch-Sch\u00f6nlein purpura nephritis. Clin. Exp. Med. 19, 449\u2013456 (2019).","journal-title":"Clin. Exp. Med."},{"key":"1420_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-1117-9","volume":"19","author":"X Huang","year":"2018","unstructured":"Huang, X. et al. Significance of histological crescent formation in patients with IgA vasculitis (Henoch-Sch\u00f6nlein purpura)-related nephritis: a cohort in the adult Chinese population. BMC Nephrol. 19, 334 (2018).","journal-title":"BMC Nephrol."},{"key":"1420_CR81","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1053\/j.ajkd.2006.02.178","volume":"47","author":"R Coppo","year":"2006","unstructured":"Coppo, R. et al. Predictors of outcome in Henoch-Sch\u00f6nlein nephritis in children and adults. Am. J. Kidney Dis. 47, 993\u20131003 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"1420_CR82","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"Working Group of the International IgA Nephropathy Network and the Renal Pathology Society","year":"2009","unstructured":"Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 76, 534\u2013545 (2009).","journal-title":"Kidney Int."},{"key":"1420_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-1009-z","volume":"19","author":"K Inagaki","year":"2018","unstructured":"Inagaki, K. et al. Clinical impact of endocapillary proliferation according to the Oxford classification among adults with Henoch-Sch\u00f6nlein purpura nephritis: a multicenter retrospective cohort study. BMC Nephrol. 19, 208 (2018).","journal-title":"BMC Nephrol."},{"key":"1420_CR84","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40620-017-0457-z","volume":"31","author":"K Xu","year":"2018","unstructured":"Xu, K. et al. Value of the Oxford classification of IgA nephropathy in children with Henoch-Sch\u00f6nlein purpura nephritis. J. Nephrol. 31, 279\u2013286 (2018).","journal-title":"J. Nephrol."},{"key":"1420_CR85","first-page":"715","volume":"44","author":"Y Shi","year":"2026","unstructured":"Shi, Y., Hong, Z., Lou, B. & Zhu, C. Establishment and validation of a novel risk stratification scale in adult IgA vasculitis nephritis: a cohort study based on a systematic review and meta-analysis. Clin. Exp. Rheumatol. 44, 715\u2013722 (2026).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1420_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.103729","volume":"11","author":"L Oni","year":"2026","unstructured":"Oni, L. et al. A pathway to high quality clinical trials in IgA vasculitis nephritis: meeting proceedings from a multiprofessional international collaborative workshop. Kidney Int. Rep. 11, 103729 (2026).","journal-title":"Kidney Int. Rep."},{"key":"1420_CR87","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ki.2010.150","volume":"78","author":"E Pillebout","year":"2010","unstructured":"Pillebout, E. et al. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Sch\u00f6nlein purpura. Kidney Int. 78, 495\u2013502 (2010).","journal-title":"Kidney Int."},{"key":"1420_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.588031","volume":"7","author":"J Tan","year":"2020","unstructured":"Tan, J. et al. Global glomerulosclerosis and segmental glomerulosclerosis could serve as effective markers for prognosis and treatment of IgA vasculitis with nephritis. Front. Med. 7, 588031 (2020).","journal-title":"Front. Med."},{"key":"1420_CR89","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1631\/jzus.B1400335","volume":"16","author":"F Han","year":"2015","unstructured":"Han, F. et al. Mycophenolate mofetil plus prednisone for inducing remission of Henoch-Sch\u00f6nlein purpura nephritis: a retrospective study. J. Zhejiang Univ. Sci. B 16, 772\u2013779 (2015).","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"1420_CR90","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000341914","volume":"36","author":"P Ren","year":"2012","unstructured":"Ren, P. et al. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Sch\u00f6nlein purpura nephritis. Am. J. Nephrol. 36, 271\u2013277 (2012).","journal-title":"Am. J. Nephrol."},{"key":"1420_CR91","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/nep.12175","volume":"19","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. Leflunomide in addition to steroids improves proteinuria and renal function in adult Henoch-Schoenlein nephritis with nephrotic proteinuria. Nephrology 19, 94\u2013100 (2014).","journal-title":"Nephrology"},{"key":"1420_CR92","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJMoa1917197","volume":"383","author":"E Webb","year":"2020","unstructured":"Webb, E. et al. Compression therapy to prevent recurrent cellulitis of the leg. N. Engl. J. Med. 383, 630\u2013639 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1420_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152209","volume":"61","author":"M Sestan","year":"2023","unstructured":"Sestan, M. et al. Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: multicenter international study. Semin. Arthritis Rheum. 61, 152209 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1420_CR94","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1001\/archderm.1995.01690240061009","volume":"131","author":"G Sais","year":"1995","unstructured":"Sais, G., Vidaller, A., Jucgla, A., Gallardo, F. & Peyri, J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch. Dermatol. 131, 1399\u20131402 (1995).","journal-title":"Arch. Dermatol."},{"key":"1420_CR95","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00431-019-03409-5","volume":"178","author":"C Roman","year":"2019","unstructured":"Roman, C., Dima, B., Muyshont, L., Schurmans, T. & Gilliaux, O. Indications and efficiency of dapsone in IgA vasculitis (Henoch-Sch\u00f6nlein purpura): case series and a review of the literature. Eur. J. Pediatr. 178, 1275\u20131281 (2019).","journal-title":"Eur. J. Pediatr."},{"key":"1420_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152870","volume":"75","author":"A Glatre","year":"2025","unstructured":"Glatre, A. et al. Treatment strategies and outcomes in adult relapsing or refractory cutaneous IgA vasculitis: a multicenter retrospective cohort study. Semin. Arthritis Rheum. 75, 152870 (2025).","journal-title":"Semin. Arthritis Rheum."},{"key":"1420_CR97","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1053\/j.ajkd.2011.12.015","volume":"59","author":"JF Augusto","year":"2012","unstructured":"Augusto, J. F. et al. Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Sch\u00f6nlein purpura in adults: a case series. Am. J. Kidney Dis. 59, 663\u2013669 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"1420_CR98","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","volume":"108","author":"Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group","year":"2025","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 108, S1\u2013S71 (2025).","journal-title":"Kidney Int."},{"key":"1420_CR99","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi, C. et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353, 883\u2013887 (1999).","journal-title":"Lancet"},{"key":"1420_CR100","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv, J. et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327, 1888\u20131898 (2022).","journal-title":"JAMA"},{"key":"1420_CR101","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/ckj\/sfaa251","volume":"14","author":"E Van de Perre","year":"2021","unstructured":"Van de Perre, E., Jones, R. B. & Jayne, D. R. W. IgA vasculitis (Henoch-Sch\u00f6nlein purpura): refractory and relapsing disease course in the adult population. Clin. Kidney J. 14, 1953\u20131960 (2021).","journal-title":"Clin. Kidney J."},{"key":"1420_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043977","author":"B Nguyen","year":"2023","unstructured":"Nguyen, B. et al. Efficacy and safety of plasma exchange as an adjunctive therapy for rapidly progressive IgA nephropathy and Henoch-Sch\u00f6nlein purpura nephritis: a systematic review. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24043977 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1420_CR103","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Kidney Int. 105, S71\u2013S116 (2024).","journal-title":"Kidney Int."},{"key":"1420_CR104","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1093\/ndt\/gfn209","volume":"23","author":"G Moroni","year":"2008","unstructured":"Moroni, G. et al. Renal transplantation in adults with Henoch-Sch\u00f6nlein purpura: long-term outcome. Nephrol. Dial. Transpl. 23, 3010\u20133016 (2008).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1420_CR105","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14431","volume":"30","author":"A Ebadinejad","year":"2025","unstructured":"Ebadinejad, A. et al. Outcomes in patients with Henoch-Sch\u00f6nlein purpura after kidney transplantation: a propensity score matched study. Nephrology 30, e14431 (2025).","journal-title":"Nephrology"},{"key":"1420_CR106","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 100, S1\u2013S276 (2021).","journal-title":"Kidney Int."},{"key":"1420_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2020.104035","volume":"49","author":"F Maritati","year":"2020","unstructured":"Maritati, F., Canzian, A., Fenaroli, P. & Vaglio, A. Adult-onset IgA vasculitis (Henoch-Sch\u00f6nlein): update on therapy. Presse Med. 49, 104035 (2020).","journal-title":"Presse Med."},{"key":"1420_CR108","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin, L. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med. 371, 1771\u20131780 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1420_CR109","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.40339","volume":"70","author":"F Maritati","year":"2018","unstructured":"Maritati, F. et al. Brief report: rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Sch\u00f6nlein). Arthritis Rheumatol. 70, 109\u2013114 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1420_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102490","volume":"19","author":"J Hernandez-Rodriguez","year":"2020","unstructured":"Hernandez-Rodriguez, J. et al. Rituximab treatment for IgA vasculitis: a systematic review. Autoimmun. Rev. 19, 102490 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1420_CR111","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/art.70055","volume":"78","author":"A Mahajan","year":"2026","unstructured":"Mahajan, A. et al. Rituximab versus cyclophosphamide for IgA vasculitis. Arthritis Rheumatol. 78, 1188\u20131191 (2026).","journal-title":"Arthritis Rheumatol."},{"key":"1420_CR112","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/rheumatology\/kew286","volume":"55","author":"E Van de Perre","year":"2016","unstructured":"Van de Perre, E. et al. Successful outcome using bortezomib in adult refractory IgA vasculitis: a case report. Rheumatology 55, 2089\u20132091 (2016).","journal-title":"Rheumatology"},{"key":"1420_CR113","first-page":"20","volume":"10","author":"S Lundberg","year":"2017","unstructured":"Lundberg, S., Westergren, E., Smolander, J. & Bruchfeld, A. B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin. Kidney J. 10, 20\u201326 (2017).","journal-title":"Clin. Kidney J."},{"key":"1420_CR114","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/ndt\/gfaf210","volume":"41","author":"R Zhang","year":"2026","unstructured":"Zhang, R. et al. Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy. Nephrol. Dial. Transpl. 41, 786\u2013792 (2026).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1420_CR115","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s11739-022-02968-0","volume":"17","author":"B Farisogullari","year":"2022","unstructured":"Farisogullari, B. et al. Biologics for immunoglobulin A vasculitis: targeting vasculitis or comorbid disease? Intern. Emerg. Med. 17, 1599\u20131608 (2022).","journal-title":"Intern. Emerg. Med."},{"key":"1420_CR116","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette, R. et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402, 859\u2013870 (2023).","journal-title":"Lancet"},{"key":"1420_CR117","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","volume":"394","author":"V Perkovic","year":"2026","unstructured":"Perkovic, V. et al. Sibeprenlimab in IgA nephropathy - interim analysis of a phase 3 trial. N. Engl. J. Med. 394, 635\u2013646 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1420_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2089-2","volume":"21","author":"A Ho\u010devar","year":"2019","unstructured":"Ho\u010devar, A., Tomsic, M., Jurcic, V., Perdan Pirkmajer, K. & Rotar, Z. Predicting gastrointestinal and renal involvement in adult IgA vasculitis. Arthritis Res. Ther. 21, 302 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1420_CR119","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.semarthrit.2021.03.002","volume":"51","author":"S Gendreau","year":"2021","unstructured":"Gendreau, S. et al. Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. Semin. Arthritis Rheum. 51, 436\u2013441 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1420_CR120","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jaad.2019.12.037","volume":"82","author":"E Baumrin","year":"2020","unstructured":"Baumrin, E. et al. Prognostic implications of normal or minimal urinary findings on long-term renal impairment in adults with Henoch-Sch\u00f6nlein purpura. J. Am. Acad. Dermatol. 82, 1393\u20131399 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1420_CR121","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdin.2022.05.004","volume":"8","author":"BG Kelly","year":"2022","unstructured":"Kelly, B. G. et al. Navigating the initial diagnosis and management of adult IgA vasculitis: a review. JAAD Int. 8, 71\u201378 (2022).","journal-title":"JAAD Int."},{"key":"1420_CR122","volume":"2","author":"D Hahn","year":"2023","unstructured":"Hahn, D., Hodson, E. M. & Craig, J. C. Interventions for preventing and treating kidney disease in IgA vasculitis. Cochrane Database Syst. Rev. 2, CD005128 (2023).","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01420-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01420-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01420-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:02:32Z","timestamp":1790629352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01420-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":122,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1420"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01420-3","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"28 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, in footnote a of Table 3, the wrong reference was given for \u201cthe grading system of the Oxford Centre of Evidence-Based Medicine\u201d. This has now been corrected to ref. 37 in the HTML and PDF versions of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.A.-V. has received consulting and speaker fees from Argentrix, AstraZeneca and CSL Vifor. J.B. has received research grants from Alexion, Argenx, Calliditas Therapeutics, Novartis and Travere Therapeutics; and has served as a medical\/scientific adviser for Alexion, Argenx, Biogen, Biohaven, Calliditas, Dimerix, Novartis, Otsuka, Roche, Takeda, Travere Therapeutics, Vera Therapeutics and Vertex. G.B. has received honoraria from AstraZeneca, Eli Lilly, AbbVie and Otsuka, and research grants from AstraZeneca and MSD. A.Br. has received consultation fees and speaker honoraria from AstraZeneca. A.By. has received speaker fees from LEO Pharma; and has participated in advisory boards with Alexion, Amgen, Bayer, Boehringer Ingelheim, CSL, Fresenius, Otsuka and Stada. A.E. has received grants from AstraZeneca, Novartis and Vifor. J.F. has received lecture and\/or consultancy honoraria from Alexion, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Calliditas, CSL Vifor, Novartis, Omeros, Otsuka, Roche, Sobi, Stada, Travere, Tymberline, Vera Therapeutics and Vertex; and has served on Data Safety Monitoring Boards for AstraZeneca, Novo Nordisk and Visterra. D.J. has received consulting and speaker fees from Alentis, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Fate, GSK, Kessai, Nkarta, Novartis, Otsuka, Roche\/Genentech, Takeda, UCB and CSL Vifor, and research grants from CSL Vifor and Roche\/Genentech. A.K. has received consulting fees from Novartis, Roche and Vifor. L.O. provides expert consultancy for Alexion, Alentis Therapeutics, Aurinia Pharmaceuticals, Bedrock, BioCryst Pharmaceuticals, Biohaven Pharmaceuticals, Boehringer Ingelheim, Chinook Therapeutics, Dimerix, Eloxx, Hansa Biopharma, Novartis, Roche Products, Santhera Pharmaceuticals, Sandoz and Travere Therapeutics. E.P. provides expert consultancy for Alexion, AstraZeneca, Novartis, Vera Therapeutics and Vifor. A.V. has received consulting and speaker fees from Amgen, AstraZeneca, CSL Vifor, GSK, Otsuka and Zenas Bio, research grants from AstraZeneca and GSK, and royalties from Medscape and UpToDate; and has served on a Data Safety Monitoring Board for Novartis. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}